手术与5%咪喹莫特治疗结节及浅表基底细胞癌:SINS随机对照试验5年结果
SINS非劣效随机对照试验5年数据显示,5%咪喹莫特乳膏治疗低危部位浅表或结节型基底细胞癌的5年成功率82.5%,低于手术的97.7%(RR=0.84,95%CI 0.77-0.91,P<0.001)。多数咪喹莫特治疗失败发生在第1年,但对早期应答的病灶可持续获益。
要点
- 手术5年成功率97.7%,显著优于咪喹莫特的82.5%。
- 咪喹莫特治疗失败大多发生在治疗第1年内。
- 对早期应答的病灶,局部咪喹莫特可持续获益。
核心结论
- 手术在5年成功率上显著优于5%咪喹莫特治疗低危部位浅表或结节型基底细胞癌。
- 对早期应答的病灶,局部咪喹莫特治疗显示出持续获益。
研究设计与样本
- 非劣效随机对照试验SINS,501例参与者随机分配至5%咪喹莫特乳膏组或 excision手术组。
- 咪喹莫特用法为每日1次(浅表型6周,结节型12周),手术切缘4mm。
- 主要终点为3年皮肤科复查时临床无初始失败或复发迹象,5年成功定义为3年成功加上至5年无复发。
- 401例参与3年改良意向性分析,其中383例(96%)有5年数据。
主要发现
- 5年成功率:咪喹莫特组82.5%(170/206),手术组97.7%(173/177)。
- 咪喹莫特成功的相对风险为0.84(95%CI 0.77-0.91,P<0.001)。
- 3年成功率:咪喹莫特组83.6%(178/213),手术组98.4%(185/188)。
- 多数咪喹莫特治疗失败发生在第1年。
关键数值与推荐
- 5年成功定义为3年成功加上通过医院、组织病理学和全科医生记录确认无复发。
临床怎么用
- 手术应作为低危部位浅表或结节型基底细胞癌的优选治疗。
- 对早期应答的病灶,局部咪喹莫特可作为持续获益的选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We previously reported modest clinical 3-year benefit for topical imiquimod compared with surgery for superficial or nodular basal cell carcinoma at low-risk sites in our noninferiority randomized controlled SINS trial. Here we report 5-year data. Participants were randomized to imiquimod 5% cream once daily (superficial basal cell carcinoma, 6 weeks; nodular basal cell carcinoma, 12 weeks) or excisional surgery (4-mm margin). The primary outcome was clinical absence of initial failure or signs of recurrence at the 3-year dermatology review. Five-year success was defined as 3-year success plus absence of recurrences identified through hospital, histopathology, and general practitioner records. Of 501 participants randomized, 401 contributed to the modified intention-to-treat analyses at year 3 (primary outcome), 383 (96%) of whom had data at year 5. Five-year success rates for imiquimod were 82.5% (170/206) compared with 97.7% (173/177) for surgery (relative risk of imiquimod success = 0.84, 95% confidence interval = 0.77-0.91, P < 0.001). These were comparable to year 3 success rates of 83.6% (178/213) and 98.4% (185/188) for imiquimod and surgery, respectively. Most imiquimod treatment failures occurred in year 1. Although surgery is clearly superior to imiquimod, this study shows sustained benefit for lesions that respond early to topical imiquimod.
引用
- Williams HC, Bath-Hextall F, Ozolins M, et al. Surgery Versus 5% Imiquimod for Nodular and Superficial Basal Cell Carcinoma: 5-Year Results of the SINS Randomized Controlled Trial. J Invest Dermatol. 2016. PMID: 27932240. doi:10.1016/j.jid.2016.10.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。